SCYNEXIS (STU:135) Beta: 0.5594 (As of Jun. 26, 2026)


STU:135 SCYNEXIS Inc STU:135
43 GF Score
Price €4.84
GF Value €29.55
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is SCYNEXIS Beta?

SCYNEXIS STU:135 43 Beta is 0.5594 as of Jun. 26, 2026. GuruFocus rates STU:135 with a GF Score™ of 43/100 and a GF Value™ of €29.55 (Possible Value Trap). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), SCYNEXIS's Beta is 0.5594.


SCYNEXIS  (STU:135) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


SCYNEXIS Beta Related Terms


SCYNEXIS Beta Historical Data

* Premium members only.

The historical data trend for SCYNEXIS's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SCYNEXIS Beta Chart

SCYNEXIS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.78 1.05 0.47 0.92 0.63

SCYNEXIS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 0.35 0.58 0.63 0.94

STU:135 vs ETST, BGM, INCR: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Beta distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Beta falls into.


STU:135
43GF Score
SCYNEXIS Inc STU:135
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SCYNEXIS Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.5594 mean?
SCYNEXIS (STU:135) has a Beta of 0.5594 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for SCYNEXIS and its competitors.
Is SCYNEXIS's Beta too high?
SCYNEXIS's current Beta is 0.5594. Overall, SCYNEXIS has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's Beta compare to ETST and BGM?
SCYNEXIS's Beta of 0.5594 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for SCYNEXIS and its competitors. SCYNEXIS's current Beta is 0.5594. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
Based on GuruFocus' analysis, SCYNEXIS (STU:135) is currently considered Possible Value Trap. The stock's GF Value™ is €29.55, compared to a current price of €4.84 — trading 83.6% below its estimated fair value. The current Beta is 0.5594. SCYNEXIS's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For SCYNEXIS (STU:135), the current Beta is 0.5594 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SCYNEXIS (STU:135) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of €4.84 is trading 83.6% below its estimated GF Value™ of €29.55. GuruFocus considers SCYNEXIS to be Possible Value Trap.

Key valuation signals for STU:135:

  • Beta: 0.5594
  • GF Value™: €29.55 vs. price of €4.84 (83.6% below fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the STU:135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SCYNEXIS Business Description

Other Exchanges SCYX:USA0L49:UK
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
43GF Score

Get the complete analysis for STU:135

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.84
Price
€29.55
GF Value